drugset
drugset / Trial / NCT04249284

Pharmacokinetics (Drug Levels in Blood) of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants

NCT04249284 ↗

Phase 1 Completed 18 enrolled Bristol-Myers Squibb
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to characterize the pharmacokinetics (the way the body absorbs, distributes and eliminates the drug) of BMS 986165 given in the form of various prototypes of solid tablets to healthy participants.

Timeline

Start
2020-02-06
Primary completion
2020-03-15
Completion
2020-03-15

Drugs

EvaluationDrugModalityDoseRoute
Subject CRAVACITINIB Small molecule — —

Indications

No indication recorded.